Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 19/20 | 1.00 |
| ▸ | CCNH | P51946 | 19/20 | 1.00 |
| ▸ | CDK9 | P50750 | 18/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 17/20 | 1.00 |
| ▸ | CCNK | O75909 | 16/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 16/20 | 1.00 |
| ▸ | CDK13 | Q14004 | 13/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 11/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 10/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.61 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190873 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL20209077 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL20209095 | 0.94 | CDK7 (0.89) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL23609804 | 0.93 | CDK7 (0.86) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL20209059 | 0.92 | CDK7 (0.86) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL20209066 | 0.91 | CDK7 (1.00) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL16665137 | 0.90 | CDK7 (0.82) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL22930830 | 0.90 | CDK7 (0.82) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL18047350 | 0.90 | CDK7 (0.82) | CDK7CCNHCDK9CCNT1CCNK | |
| SCHEMBL23609900 | 0.88 | CDK7 (0.79) | CDK7CCNHCDK9CCNT1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932625-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3544971-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3544971-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2018098361-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317105-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNH 45/4885CDK9 22/4885 |
| US-11932625-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | CDK7 41/4885CCNH 45/4885CDK9 22/4885 |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNH 45/4885CDK9 22/4885 |
| US-11306070-B2 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | CDK12, CDK1, CDK13 | CDK7 41/4885CCNH 45/4885CDK9 22/4885 |
| US-20200361906-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNH 45/4885CDK9 22/4885 |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | CDK7, CDC7, CDK8 | CDK7 1/4885CCNH 45/4885CDK9 5/4885 |
| US-20220213067-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | CDK7 41/4885CCNH 45/4885CDK9 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.